PURASORB PDLG 8508 is a poly(DL-lactide-co-glycolide) copolymer supplied as white to off-white granules. The grade designation encodes the 85:15 molar ratio of DL-lactide to glycolide and a midpoint inherent viscosity of 0.8 dL/g measured in chloroform at 25 °C and 0.1 g/dL by a capillary viscometry method aligned with ISO 1628-1:2021. The standard end-group configuration is acid-terminated; this should be confirmed on the certificate of analysis because acid and ester termination differ in hydrolytic induction period. Typical lot release data for this grade include residual glycolide and lactide each below 0.5% w/w, water content below 0.5% w/w, and tin catalyst residue below 200 ppm. The molecular weight distribution is reported by gel-permeation chromatography with refractive index detection; the weight-average molecular weight is batch-specific and should not be inferred from inherent viscosity alone. The polymer is intended for parenteral drug-delivery matrices, including solvent-based microspheres, in situ forming depots, and melt-extruded implants, but it is not a finished dosage form. It is soluble in dichloromethane, chloroform, acetone, ethyl acetate, tetrahydrofuran, and dimethyl sulfoxide, and insoluble in water, ethanol, and hexane.

What Controls Hydrolytic Degradation Rate in an 85:15 Copolymer?

Hydrolytic degradation of PLGA copolymers proceeds by bulk erosion rather than surface erosion, and the rate is governed by water accessibility, copolymer ratio, molecular weight, end-group chemistry, and the local pH generated by acidic degradation products. In an 85:15 DL-lactide:glycolide copolymer, the higher lactide content increases chain hydrophobicity and reduces equilibrium water uptake relative to a 50:50 copolymer of similar molecular weight. The dry glass transition temperature of 85:15 PLGA is commonly reported in the 45–50 °C range, whereas 50:50 PLGA is generally 40–45 °C; both values depend on molecular weight, residual solvent, and thermal history. The amorphous nature of PDLG 8508 eliminates crystalline blocking of water penetration, but hydrolytic chain scission remains slower than in lower-lactide PLGA grades because glycolide ester bonds are more hydrophilic and more labile.

Mass loss is preceded by a reduction in molecular weight. Acid-terminated PDLG 8508 exhibits a higher initial concentration of carboxyl end groups than an ester-terminated analogue, and this can accelerate early water uptake and chain scission. In phosphate-buffered saline at 37 °C and pH 7.4, the degradation profile of high-lactide PLGA microspheres is typically slower than that of 50:50 or 75:25 copolymers; however, the exact mass-loss curve depends on particle size, porosity, drug loading, and buffer molarity. Published data for this specific configuration is limited, so formulation-specific degradation studies are required.

For solvent-based microsphere fabrication, a representative lab-scale process disperses a 10–20% w/w polymer solution in dichloromethane into an aqueous continuous phase containing 0.5–2.0% w/w polyvinyl alcohol using an IKA Ultra-Turrax T25 digital rotor-stator at 10,000–15,000 rpm. The resulting oil-in-water emulsion is transferred to a jacketed 2 L glass reactor equipped with an overhead anchor stirrer operating at 300 rpm and 35 °C. The solvent extraction step is a narrow process boundary: rapid initial evaporation creates a dense surface skin that traps residual dichloromethane and increases initial burst, while excessively slow extraction can allow droplet coalescence and broaden the particle size distribution. Laser diffraction particle size analysis per ISO 13320:2020 should be used to track the volume-median diameter and span.

Residual dichloromethane plasticizes the copolymer and depresses its effective glass transition temperature. Differential scanning calorimetry at 10 K/min under nitrogen according to ISO 11357-2:2020 shows the dry Tg, but the wet Tg during primary drying is lower because of residual solvent. Drying should therefore be staged below the plasticized Tg, typically at 25–35 °C and ≤0.1 mbar for 24–48 h, until headspace gas chromatography per USP <467> demonstrates that residual solvent in the final dosage form is below the applicable limit. In high-humidity environments above 60% relative humidity, the polymer must be handled under nitrogen or dry air to prevent hydrolytic degradation during processing.

In in situ forming implant formulations, PDLG 8508 is dissolved at 20–40% w/w in N-methyl-2-pyrrolidone, dimethyl sulfoxide, or benzyl benzoate. Solvent water miscibility controls the phase inversion rate and the initial release: N-methyl-2-pyrrolidone exchanges rapidly with aqueous fluid and produces a more porous depot, while benzyl benzoate produces a slower phase inversion and a denser matrix. The 0.8 dL/g inherent viscosity raises solution viscosity relative to PDLG 5004; syringeability through a 21 G needle may therefore require a lower polymer concentration or a higher injection force specification. Sterile filtration of the polymer solution is generally not feasible because of viscosity.

When a 50:50 PLGA Grade Is Replaced in Long-Acting Injectable Development

Replacement of a 50:50 PLGA of similar inherent viscosity with PDLG 8508 typically slows the hydration front and reduces the early release phase because the matrix remains glassy longer and has lower water permeability. This shift is not a simple linear extension of release duration. The degradation-controlled phase depends on the reduced glycolide fraction, while the diffusion-controlled phase is governed by the higher dry Tg and the lower equilibrium water content. A formulation change from PDLG 7507 to PDLG 8508 further reduces glycolide content from 25% to 15%, which delays oligomer solubilization and pore formation in the matrix.

Direct substitution requires re-qualification of in vitro release, in vivo pharmacokinetics, and residual monomer clearance. The initial burst may decrease, but the later release plateau can be more sensitive to pH-buffering capacity in the subcutaneous or intramuscular environment. In large implants, acidic degradation products can accumulate and produce autocatalytic core degradation; this effect is mass-transport limited and is not captured by small-scale microsphere release alone. Published data for this specific grade in a generic long-acting injectable is limited, so the design space must be generated with the intended drug substance and sterilization method.

Table 1 compares adjacent PURASORB PDLG grades commonly screened during sustained-release formulation. Inherent viscosity values are midpoint values from the manufacturer’s product range; lot-specific specifications appear on certificates of analysis.

Accelerated Degradation Testing and pH Microenvironment Effects

Accelerated in vitro conditions at elevated temperature may not provide a linear prediction of PDLG 8508 performance because the copolymer is glassy at physiological temperature; raising the test temperature above the hydrated Tg changes segmental mobility and water diffusion, creating an artificial acceleration factor. In vitro release testing at 37 °C in phosphate-buffered saline at pH 7.4 remains the primary screen. If accelerated conditions are used, the temperature offset should remain below the onset of the hydrated glass transition, which is lower than the dry value. Modulated DSC or dynamic mechanical analysis in phosphate-buffered saline can quantify the hydrated Tg.

Hydrolysis generates lactic acid and glycolic acid, and the local pH within a large depot may fall to 3–5. This autocatalytic effect accelerates core degradation and can produce hollow or porous structures visible by scanning electron microscopy. Use of a higher-buffer-capacity release medium, such as 0.1 M phosphate, can partially suppress this autocatalysis but may overestimate in vivo stability because tissue buffering capacity is limited. For this reason, accelerated degradation data should not be extrapolated without a physiologically based mass-transfer model.

Melt extrusion of PDLG 8508 requires pre-drying to ≤0.1% w/w water and should be conducted below 150 °C in a twin-screw extruder with a short residence time, because thermal and hydrolytic chain scission accelerate sharply above the melting onset of the lactide-rich phase. Gamma irradiation at 25 kGy can reduce molecular weight; the extent depends on dose rate, oxygen, and irradiation temperature, and published data for this specific configuration is limited. Terminal sterilization must therefore be qualified on the finished implant rather than assumed from raw-polymer stability.

Compliance of the raw copolymer with pharmacopoeial or device standards is limited to its role as an excipient or starting material. Finished long-acting injectables must be qualified under applicable regulatory frameworks. For implantable devices, biological evaluation is performed on the sterilized final device according to ISO 10993-1:2018 and subsequent parts, not on the polymer alone. Residual solvents in the finished product are controlled under ICH Q3C(R8); dichloromethane, if used, is a Class 2 solvent with a permitted daily exposure of 6.0 mg/day, and the concentration limit depends on the administered volume. The polymer manufacturer’s specification for residual monomers and tin is not automatically equivalent to finished-product acceptance criteria.

Storage requires sealed, moisture-impermeable packaging under refrigeration or controlled room temperature. Exposure to relative humidity above 60% initiates hydrolytic degradation during storage. The product should be equilibrated to ambient temperature before opening to avoid condensation. If water content exceeds the specification, vacuum drying below the glass transition temperature may be used, but chain scission already initiated cannot be reversed.